Ro, Eli Lilly

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
BofA analyst Allen Lutz notes Ro Health, a direct competitor to Hims & Hers (HIMS), announced that the company is working with Eli Lilly ...
Eli Lilly (NYSE:LLY) plans to streamline patient access to its weight-loss drug Zepbound by offering single-dose vials ...
"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...
Shares of Hims & Hers Health Inc. slid to a three-week low on Wednesday before recovering some losses, even as retail ...